drugset
drugset / Trial / NCT05193851

Evaluate the Safety and Pharmacokinetics of Ricolinostat

NCT05193851 ↗

Phase 1 Completed 12 enrolled Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

This study is an open-label, phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.

Timeline

Start
2022-01-12
Primary completion
2022-01-30
Completion
2023-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ricolinostat Small molecule — —

Indications

peripheral nervous system disorder